Pulse Biosciences (NASDAQ:PLSE) Shares Up 2% - Time to Buy?

Key Points

• Pulse Biosciences shares rose 2% during trading, reaching a high of $15.09, with a significant increase in trading volume compared to the average.
• Oppenheimer initiated coverage with an "outperform" rating and a target price of $22.00 for Pulse Biosciences, indicating potential growth.
• Institutional investors collectively own 76.95% of Pulse Biosciences, with notable increases in stakes from major names like Vanguard Group and Deutsche Bank.

Pulse Biosciences, Inc (NASDAQ:PLSE - Get Free Report)'s share price traded up 2% on Thursday . The company traded as high as $15.09 and last traded at $15.02. 217,195 shares changed hands during mid-day trading, an increase of 53% from the average session volume of 142,021 shares. The stock had previously closed at $14.73.

Wall Street Analysts Forecast Growth

Separately, Oppenheimer started coverage on shares of Pulse Biosciences in a report on Monday, July 7th. They set an "outperform" rating and a $22.00 target price for the company.

Pulse Biosciences Stock Performance

The firm's 50-day simple moving average is $15.81 and its 200 day simple moving average is $17.15.

Pulse Biosciences (NASDAQ:PLSE - Get Free Report) last released its quarterly earnings data on Thursday, May 8th. The company reported ($0.25) earnings per share for the quarter.

Insider Buying and Selling at Pulse Biosciences

In other news, CTO Darrin Uecker sold 15,000 shares of the company's stock in a transaction that occurred on Thursday, June 12th. The shares were sold at an average price of $16.40, for a total transaction of $246,000.00. Following the completion of the sale, the chief technology officer owned 137,872 shares of the company's stock, valued at approximately $2,261,100.80. This represents a 9.81% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Company insiders own 71.50% of the company's stock.

Hedge Funds Weigh In On Pulse Biosciences

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Tower Research Capital LLC TRC increased its position in shares of Pulse Biosciences by 98.1% during the fourth quarter. Tower Research Capital LLC TRC now owns 1,692 shares of the company's stock worth $29,000 after buying an additional 838 shares during the period. AlphaQuest LLC increased its position in shares of Pulse Biosciences by 68.0% during the first quarter. AlphaQuest LLC now owns 3,116 shares of the company's stock worth $50,000 after buying an additional 1,261 shares during the period. Rhumbline Advisers increased its position in shares of Pulse Biosciences by 6.3% during the first quarter. Rhumbline Advisers now owns 27,375 shares of the company's stock worth $440,000 after buying an additional 1,614 shares during the period. Farther Finance Advisors LLC grew its holdings in Pulse Biosciences by 24.6% in the first quarter. Farther Finance Advisors LLC now owns 8,998 shares of the company's stock worth $143,000 after purchasing an additional 1,778 shares during the period. Finally, Wells Fargo & Company MN grew its holdings in Pulse Biosciences by 27.1% in the fourth quarter. Wells Fargo & Company MN now owns 11,315 shares of the company's stock worth $197,000 after purchasing an additional 2,416 shares during the period. 76.95% of the stock is currently owned by institutional investors and hedge funds.

About Pulse Biosciences

Pulse Biosciences, Inc operates as a novel bioelectric medicine company. The company offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology.